지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Filgrastim is used as an indispensable adjuvant drug to reduce the degree and duration of chemo-therapy-induced neutropenia. The purpose of this research is to study the use of filgrastim by reviewing retrospective medical records of breast cancer patients who have been treated by filgtastim in the National Cancer Center. 84 patients have received 323 cycles of chemotherapy, of which 134 cycles were treated by filgrastim (41.5%). Among those 134 cycles, 34 were for prophylaxis (21.6%), and 100 for treatment of neutropenia (74.6%). The frequence of filgrastim usage was more than 50% in frequency with regimens containing docetaxel. For prophylaxis, the median of filgrastim initiation was measured on the day of chemotherapy (-3rd-13th). For the treatment, on the other hand, the median appeared on the 9th day (4th-21st) after chemotherapy, which showed very wide distribution. Time to filgrastim initiation ranged between the 7th and the 9th day after chemotherapy in docetaxel+doxorubicin combination regimen and docetaxel single regimen, whereas it showed after the 10th day in doxorubicin+cyclophosphamide combination regimens. For the treatment, 48 out of 65 patients (73.8%) in 63 cycles have experienced fever, had to visit the emergency room, required hospitalization, caused infection, transfusion, dosage reduction and schedule changes in spite of using filgrastim with chemotherapy. For prophylaxis, 11 out of 19 patients (57.9%) in 11 cycles have experienced the same results. In conclusion, the guideline of time to the initiation and the last is required for cost-effective administration of filgrastim because of the difference occurring ANC nadir, the severity and duration of neutropenia by chemotherapy regimens.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
미만성 거대 B 세포 림프종 환자에서 Filgrastim 사용이 PET/CT 영상에 미치는 영향에 대한 고찰
핵의학기술
2009 .01
-
항암치료를 받는 미만성거대비세포 림프종 환자에서 페그필그라스팀에 대한 효용성 평가
한국임상약학회지
2015 .01
-
Which One is More Effective, Filgrastim or Lenograstim, During Febrile Neutropenia Attack in Hospitalized Patients with Solid Tumors?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
미만성 거대 B형 세포 림프종 환자에서 CHOP 항암 치료와 Filgrastim 투여 후 발생한 폐쇄세기관지기질화폐렴 1례
Tuberculosis and Respiratory Diseases
2005 .01
-
Comparison with severity of neutropenia after administration of docetaxel, adriamycin, cyclophosphamide (TAC) and adriamycin, cyclophosphamide, docetaxel (ACT) for granulocyte colony-stimulating factor (G-CSF filgrastim) use and body mass index in breast cancer
대한임상종양학회 학술대회지
2010 .09
-
소아기 호중구 감소증
Clinical and Experimental Pediatrics
2009 .01
-
Chemotherapy in elderly breast cancer patients
대한임상종양학회 학술대회지
2011 .03
-
Chemotherapy of inflammatory breast cancer
대한외과학회 학술대회 초록집
2013 .11
-
암의 화학 요법
대한간호
1978 .01
-
항암 화학요법을 받는 유방암 환자의 삶의 질에 관한 연구
성인간호학회지
2004 .03
-
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
Annals of Surgical Treatment and Research
2018 .05
-
Chemotherapy : Is it needed?
대한외과학회 학술대회 초록집
2015 .11
-
암환자가 체험한 화학요법의 의미
간호행정학회지
1998 .02
-
항암화학요법을 받은 유방암 환자의 인지기능
Asian Oncology Nursing
2012 .02
-
Breast Conservation Surgery after Primary Chemotherapy in Breast Cancer
대한외과학회 학술대회 초록집
2005 .10
-
유방암 환자에서 항암화학요법 후 인지기능과 후각기능의 변화 : 예비연구
생물치료정신의학
2017 .06
-
항암요법의 원칙
대한외과학회 학술대회 초록집
2003 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0